TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02990546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midodrine
Description: Midodrine will be given to treatment arm as enteral medication

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients in the control arm will receive standard of care for septic shock
Study: NCT02747381

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Description: 1-alpha hydroxy cholecalciferol 1 mcg
Study: NCT01760564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat
Description: miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.
Study: NCT01683149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan will be given by mouth as outlined in treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be given by mouth as outlined in treatment arm.
Study: NCT03899324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide white, oblong, scored tablet
Description: Bumetanide with a titration period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo white, oblong, scored tablet
Description: placebo intake identically to group 1
Study: NCT01353001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Plus Aerobic Training
Description: Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet plus Resistance Training
Description: Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
Study: NCT05194046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg 1capsule
Description: will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg 1capsule
Description: will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg 1capsule
Description: will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg 1capsule
Description: will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg 1capsule
Description: will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500Mg Cap
Description: Amoxicilin 500Mg 2 capsules will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500Mg Cap
Description: Amoxicilin 500Mg 2 capsules will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500Mg Cap
Description: Amoxicilin 500Mg 2 capsules will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500Mg Cap
Description: Amoxicilin 500Mg 2 capsules will be orally administered
Study: NCT00854373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bravelle(follicle stimulating hormone)
Description: One dose of 6 amps of Bravelle given at the same time as HCG ovulation trigger.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline ( placebo)
Description: 1 cc of Normal Saline (placebo) given at the same time as HCG ovulation trigger.
Study: NCT05194046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500Mg Cap
Description: Amoxicilin 500Mg 2 capsules will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500Mg Cap
Description: Amoxicilin 500Mg 2 capsules will be orally administered
Study: NCT00453817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferucarbotran (iron-based MRI contrast agent)
Description: islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet transplantation
Description: intraportal percutaneous islet transplantation
Study: NCT05194046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500Mg Tab
Description: Amoxicilin 500Mg 1 tablet will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500Mg Tab
Description: Amoxicilin 500Mg 1 tablet will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500Mg Tab
Description: Amoxicilin 500Mg 1 tablet will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500Mg Tab
Description: Amoxicilin 500Mg 1 tablet will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500Mg Tab
Description: Amoxicilin 500Mg 1 tablet will be orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500Mg Tab
Description: Amoxicilin 500Mg 1 tablet will be orally administered
Study: NCT02853006

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood and respiratory fluids sampling
Description: In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).
Study: NCT03405740

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: No intervention
Study: NCT00453817

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Magnetic resonance imaging of the liver before and after islet transplantation (6 days, 6 weeks, 6 months, 1 year)
Study: NCT00878696

Intervention type: PROCEDURE
Intervention: TMS transcranial magnetic stimulation
Description: 200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).~The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.~Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz.
Study: NCT00613834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: 5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
Study: NCT04031612

Intervention type: DRUG
Intervention: Neoadjuvant therapy
Description: Neoadjuvant therapy
Study: NCT03959215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back in the Game
Description: A six-month programme of cognitive-behavioural therapy delivered by smartphone application. The intervention commences in the first week after ACL reconstruction. The smartphone app is delivered in parallel with usual rehabilitation care.~Usual rehabilitation care: all participants will be referred to physiotherapy following ACL reconstruction. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the treatment aims is at the clinical discretion of the treating physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual rehabilitation care
Description: Following ACL reconstruction, as per routine clinical practice, all participants will be referred to physiotherapy. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the required treatment aims is at the clinical discretion of the treating physiotherapist.
Study: NCT03432234

Intervention type: OTHER
Intervention: Biomarkers
Description: This is an observational study, there is no intervention

Intervention type: OTHER
Intervention: Biomarkers
Description: This is an observational study, there is no intervention

Intervention type: OTHER
Intervention: Biomarkers
Description: This is an observational study, there is no intervention
Study: NCT04523402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Neoadjuvant chemotherapy with GEMOX regimen before liver resection
Study: NCT03696355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0084
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0084
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Both photon and proton therapy modalities will be allowed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Both photon and proton therapy modalities will be allowed.
Study: NCT04216615

Intervention type: BEHAVIORAL
Intervention: preoperative anxiety
Description: patients who are anxious

Intervention type: BEHAVIORAL
Intervention: preoperative anxiety
Description: patients who are anxious
Study: NCT00971984

Intervention type: OTHER
Intervention: Medical records summary
Description: Summary of Medical files and laboratory results.
Study: NCT02919241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnostic interview
Description: A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnostic interview
Description: A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined interview and treatment.
Description: Intervention for this group include both the diagnostic interview to declare causes for negative thoughts, assumptions and beliefs towards dental care and one session treatment. Participants come from the Institute of Dentistry.
Study: NCT02276898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline 7%
Description: PARI Hyper-Sal™ Sodium Chloride Solution - 7%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline 0.9% (Placebo)
Study: NCT00793741

Intervention type: DRUG
Intervention: somatostatin
Description: Somatostatin may be used to suppress endogenous insulin secretion

Intervention type: DRUG
Intervention: somatostatin
Description: Somatostatin may be used to suppress endogenous insulin secretion
Study: NCT01352728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
Study: NCT02035020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma interferon
Description: IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
Study: NCT02446834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive lifestyle intervention
Description: 3 months low GI diet and exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 Receptor Agonists
Description: Use GLP-1 Receptor Agonists 3 months to treat PCOS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Use metformin 3 months to treat PCOS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Use acarbose 3 months to treat PCOS
Study: NCT04108273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational Skills Training
Description: OST targets three core organizational skills domains - Tracking Assignments, Managing Materials and Time Management - in a program consisting of sessions over 12 weeks, each training lasting about 1 hour, and corresponding 30-60 minute weekly review sessions with the parent and the child, 2-3 days following each training session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Organizational Skills Training
Description: OST targets three core organizational skills domains - Tracking Assignments, Managing Materials and Time Management - in a program consisting of sessions over 12 weeks, each training lasting about 1 hour, and corresponding 30-60 minute weekly review sessions with the parent and the child, 2-3 days following each training session.
Study: NCT03248323

Intervention type: RADIATION
Intervention: dyna-pbv
Study: NCT06325787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroid lobectomy
Description: thyroid lobectomy
Study: NCT06325787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: image-guided thermal ablation
Description: radiofrequency ablation or microwave ablation or laser ablation
Study: NCT01502735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DENV-1 PIV, 2.5 µg
Description: 2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
Study: NCT00697606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seprafilm®
Description: Seprafilm® placed at time of primary cesarean

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: no Seprafilm® used at primary cesarean
Study: NCT03202901

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B-turmactive
Description: The treatment consists of daily administration of B-TURMACTIVE®.~Treatment with B-TURMACTIVE® will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable
Study: NCT02853006

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Excised tissues
Study: NCT01086150

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Study: NCT03202901

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment consists of daily administration of placebo capsule with identical format and harmless thant B-turmactive product.~Treatment with placebo will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable
Study: NCT01086150

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine 5% patches
Description: Subject will apply patches to affected area QD for 12 hours then remove.

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine 5% patches
Description: Subject will apply patches to affected area QD for 12 hours then remove.
Study: NCT00049842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (SCH 54031)
Description: 0.5 µg/kg Weekly QW SC for 36 months
Study: NCT03353402

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: Patients with metastatic melanoma who responded to immunotherapy will serve as the fecal implant donors. The tested fecal implant will be used for two different products. The first part of the tested stool will be mixed with a saline solution, strained and infused into your bowel using colonoscopy. The second part of the tested stool will be packed into capsules. These stool capsules are at the size of standard drug-containing capsules and can be swallowed in a standard manner. Stool capsules are a common method of FMT and has been used worldwide for several years. After the colonoscopy, you will be asked to swallow the capsules. Swallowing the capsules will be conducted at the clinic, and does not require any additional procedures.
Study: NCT03236948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women for Women International Intervention
Study: NCT00952276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant
Description: 0.5 mL, Intramuscular on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant
Description: 0.5 mL, Intramuscular on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent Subvirion A/H1N1 influenza vaccine
Description: 0.5 mL, Intramuscular on Day 0
Study: NCT02273778

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI Scan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET-CT Scan

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study: NCT02021331

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement without provisionalization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate implant placement with immediate provisionalization
Study: NCT00424983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Study: NCT01086150

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine 5% patches
Description: Subject will apply patches to affected area QD for 12 hours then remove.
Study: NCT00952276

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent Subvirion A/H1N1 influenza vaccine
Description: 0.5 mL, Intramuscular on Day 0

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution
Description: 0.5 mL, Intramuscular on Day 0
Study: NCT03398122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
Study: NCT01869543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stand Alone Air Cleaner
Description: This is an environmental intervention using a stand alone air cleaner designed to reduce the air pollution levels in the home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stand Alone Air Cleaner
Description: This is an environmental intervention using a stand alone air cleaner designed to reduce the air pollution levels in the home.
Study: NCT03398122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apatinib
Description: a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor
Study: NCT04258046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib tablet
Description: Drug is supplied in 0.5 mg and 2 mg tablets
Study: NCT01176643

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care plus Yoga
Description: Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
Study: NCT02676713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pre-ovulation Decoction
Description: HuoXueXiaoYi Decoction(Bupleurum 10g, Cyperus 10g, Salvia miltiorrhiza 20g, Red peony 10g,etc)has activating blood and absorbing clots effect, can inhibit the growth of ectopic endometrium, promote follicular growth, maturity, improve ovulation and the receptivity of endometrium.
Study: NCT03550287

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental product
Description: 10 g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: 10 g/day
Study: NCT01869543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVAC Modification
Description: This is an environmental intervention that modifies the home HVAC system to include high efficiency air filtration designed to reduce the air pollution levels in the home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVAC Modification
Description: This is an environmental intervention that modifies the home HVAC system to include high efficiency air filtration designed to reduce the air pollution levels in the home.